BioCryst Pharmaceuticals (BCRX) Reports Q4 Loss, Tops Revenue Estimates
Portfolio Pulse from
BioCryst Pharmaceuticals (BCRX) reported a Q4 loss of $0.13 per share, which was wider than the Zacks Consensus Estimate of a $0.06 loss. However, the company exceeded revenue expectations.
February 24, 2025 | 2:30 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
BioCryst Pharmaceuticals reported a Q4 loss of $0.13 per share, missing the Zacks Consensus Estimate of a $0.06 loss. Despite the earnings miss, the company exceeded revenue expectations.
The earnings per share (EPS) miss is likely to negatively impact the stock price in the short term, as it was wider than expected. However, the revenue beat may mitigate some of the negative sentiment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100